Ophthalmology off the Grid by Eyetube

Blake Williamson, MD, MPH, and Gary Wörtz, MD, return for a new season of Ophthalmology off the Grid! This season, the hosts dive into the basics of training and education at the most prestigious programs in ophthalmology across the United States. In this episode, they invite Pavlina Kemp, MD, residency program director at the University of Iowa Department of Ophthalmology and Visual Sciences, and Samuel Tadros, MD, a PGY-4 ophthalmology resident, to share a state of the union on ophthalmology residency. They discuss what it takes to stand out during the application and interviewing process and find success in the field.

In this episode, Gary Wörtz, MD, invites Damien Gatinel, MD, PhD, to share insights into online ophthalmic simulators and tools to help surgeons improve refractive planning. They explore tools for corneal ablation depth predictions, IOL rotation optimization, and more. Dr. Gatinel explains how these simulations can be applied to real-world patient counseling and help ophthalmologists understand what's going on with their patients.

In this episode, hosts Blake Williamson, MD, MPH, and Gary Wörtz, MD, invite Kenneth Beckman, MD, to discuss the recent FDA approval of Epioxa (Glaukos), an advancement in corneal crosslinking for the treatment of keratoconus that does not require the removal of the corneal epithelium. Dr. Beckman shares insights into the benefits and outcomes of this procedure and details from clinical trials.

In this episode, Joaquin De Rojas, MD, and Priya Mathews, MD, MPH, join hosts Blake Williamson, MD, MPH, and Gary Wörtz, MD, to discuss how the Tecnis Odyssey IOL differs from previous presbyopia-correcting lenses and how they approach lens selection for their patients. Dr. De Rojas also shares his experience with coding and the use of AI in his practice for digesting significant amounts of data to assist with calculations and treatment algorithms.

Blake Williamson, MD, MPH, invites Steven Dell, MD, to discuss the recent release of a new presbyopia drop—VIZZ (aceclidine ophthalmic solution, 1.44%; Lenz Therapeutics). Dr. Dell outlines why this drop represents a game-changing option for presbyopia therapy. The once-daily drop lasts for 10 hours and results in a sub-2-mm pupil size to achieve significant gains in near vision. They also review the innovation cycle of this product and how patients have responded to the treatment so far.